scholarly journals US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation

Cancer ◽  
2020 ◽  
Vol 126 (19) ◽  
pp. 4270-4272
Author(s):  
Myung Sun Kim ◽  
Vinay Prasad
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Drug Administration ◽  
Trial Design ◽  
Kinase Inhibitors ◽  
Food And Drug Administration ◽  
Lymphocytic Leukemia ◽  
Bruton Tyrosine Kinase ◽  
Evidence Generation

Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Jacob Schmelz ◽  
Philip Heesen ◽  
Anish Patnaik ◽  
Travis Holder ◽  
Hun J Lee ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia ◽  
Bruton Tyrosine Kinase

Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia

2018 ◽  
Vol 25 (4) ◽  
pp. 1003-1005 ◽  
Author(s):  
Constantin A Dasanu
Keyword(s):  
Side Effects ◽  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Cancer Patients ◽  
Tyrosine Kinase Inhibitors ◽  
Side Effect ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia ◽  
Targeted Agents ◽  
Bruton Tyrosine Kinase

Although newer targeted agents improve survival in cancer patients, they have also been linked with unusual side effects. The most common side effects of Bruton tyrosine kinase inhibitors include fatigue, nausea, diarrhea, bruising, and cytopenias. We describe herein a case of an unusually severe articular syndrome with the use of ibrutinib in a patient with 17 p minus chronic lymphocytic leukemia. The severity of this side effect led to permanent discontinuation of this agent. As the causality ibrutinib-arthralgia seems legitimate, we expect further similar cases to surface in patients treated with Bruton tyrosine kinase inhibitors.

scholarly journals The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution

2020 ◽  
Vol 21 (4) ◽  
pp. 45-47
Author(s):  
Irina V. Poddubnaya ◽  
Tatyana E. Bialik ◽  
Natalya N. Glonina ◽  
Olga B. Kalashnikova ◽  
Kamil D. Kaplanov ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Lymphocytic Leukemia ◽  
First Line ◽  
Important Place ◽  
First Line Therapy ◽  
Line Therapy ◽  
Bruton Tyrosine Kinase ◽  
Adult Leukemia

Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with incidence rate of 4: 100 thousand per year, according to European data. CLL remains an incurable disease, with most patients over 60 years old. Immunochemotherapy schemes today remain the standard treatment approach for CLL. The advent of novel molecules expands possibilities of treating this disease. Targeted therapy with small molecule inhibitors of Bruton tyrosine kinase (BTK) occupies an important place in the treatment of patients with CLL, both for first-line therapy and for treatment of relapses. The drug acalabrutinib as a highly selective new generation of BTK inhibitor can be considered as an efficient and safe option for first-line therapy and for treatment of the disease relapse in patients with CLL, especially in patients with comorbidity, including cardiovascular diseases (CDV) or risk factors for CVD.

Sign in / Sign up

Export Citation Format

Share Document